氟伏沙明,临床注释-2,变异和临床注释数据

氟伏沙明

临床注释ID

1183700410

药物名称(英)

fluvoxamine

变异单倍型

CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*14

基因

CYP2D6

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

103.4375

PMID计数

计数的证据

表现型

抑郁症

表现型(英)

Depressive Disorder

最新日期

2021/4/23 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1183700410

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
1177	*14	The CYP2D614 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D614 allele in combination with a no or decreased function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a 鈥榥o recommendation鈥?for ultrarapid metabolizers. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.
1176	*10	The CYP2D610 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D610 allele in combination with a no or decreased function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a 鈥榥o recommendation鈥?for ultrarapid metabolizers. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.
1175	*6	The CYP2D66 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D66 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a 鈥榥o recommendation鈥?for ultrarapid metabolizers. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.
1174	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D65 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a 鈥榥o recommendation鈥?for ultrarapid metabolizers. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.
1173	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D64 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a 鈥榥o recommendation鈥?for ultrarapid metabolizers. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.
1172	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D61 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of fluvoxamine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a 鈥榥o recommendation鈥?for ultrarapid metabolizers. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.

临床证据

id	证据的ID	总结
4520	1449577681	CYP2D6 1/10 + 1/5 + 10/10 + 10/14 + 5/10 are not associated with increased concentrations of fluvoxamine as compared to CYP2D6 1/1.
4519	1449577638	CYP2D6 1/10 + 1/5 + 10/10 + 10/14 + 5/10 are associated with increased steady-state concentration of fluvoxamine as compared to CYP2D6 1/1.
4518	1184137435	CYP2D6 1/10 + 1/5 + 10/10 + 5/10 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 1/1.
4517	1183703493	CYP2D6 4/6 (assigned as poor metabolizer phenotype) is associated with increased AUC, Cmax and half-life time of fluvoxamine when treated with fluvoxamine in healthy individuals as compared to CYP2D6 1/1 (assigned as normal metabolizer phenotype) .
4516	1183703194	CYP2D6 1/1 is not associated with differences in plasma fluvoxamine concentration when treated with fluvoxamine in people with Depressive Disorder, Major as compared to CYP2D6 1/10 + 10/10.
4515	1183703160	CYP2D6 1/1 is not associated with differences in steady-state plasma concentrations of fluvoxamine and its demethylated metabolite fluvoxamino acid when treated with fluvoxamine in people with Depression as compared to CYP2D6 10/10 + 5/10.
4514	1183700359	CYP2D6 1/10 + 1/5 + 10/10 + 5/10 are not associated with differences in in the fluvoxamine plasma level at 100, 150, and 200 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 1/1.
4513	1183700294	CYP2D6 10/10 + 5/10 are associated with increased fluvoxamine plasma concentrations when treated with fluvoxamine in people with Mental Disorders as compared to CYP2D6 1/1.
4512	1183703504	CYP2D6 poor metabolizer is not associated with differences in the area under the serum concentration-timecurv when treated with fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.
4511	1183703487	CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.
4510	1183703476	CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.
4509	1183703205	CYP2D6 poor metabolizer is associated with increased areas under the serum concentration-time curve when treated with fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.
4508	PA166127637	Annotation of CPIC Guideline for fluvoxamine and CYP2D6

临床病史

id	类型	评论
1671	Update	Added sentence about DPWG 'no recommendation' to phenotype descriptions
1670	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1669	Update	Added sentence about no CPIC recommendation for UMs
1668	Update	modified to allele description
1667	Update	corrected typo ("Studies investigation" was changed to "Studies investigating")

最新招商产品更多>>